Polymerase Chain Reaction (PCR) COVID-19 Testing Support

This notice is being transmitted in accordance with FAR Subpart 5.2

Objective

The U.S. Department of State (DOS), Bureau of Medical Services (MED), has an immediate and ongoing need for a CLIA-certified laboratory to support both on-site (at a Government facility) and off premises specimen collection and processing for specific laboratory tests in the National Capital Region (NCR).

See attached Draft Performance Work Statement (DPWS) for additional details. Interested vendors should note that there will be changes to the PWS between now and when the final solicitation is posted.

The Government will not entertain telephone calls regarding this acquisition. All announcements and amendments made to the solicitation will be posted on beta.sam.gov.

Acquisition Information

• This requirement will be solicited as a 100% small business set-aside.
• The anticipated period of performance is comprised of a one-year base period, four, one-year option periods (plus a six-month option to extend in accordance with FAR 52.217-8).  
• All prospective offerors must be registered in the System for Award Management (SAM) in order to be eligible for award.
• The Government anticipates releasing the RFP next week (August 24-28); however, this date is subject to change.
• The contract will be awarded utilizing the best value trade-off source selection methodology. For this acquisition technical merit is more important than price. This means that the offeror's plan of operation is more significant than cost. As technical merit of the Offeror's proposals become more equal, the evaluated cost or price may become the determining factor.

Anticipated Contract Line Item Number (CLIN) Structure

CLIN    Description/Item                                             Contract Type                Unit

X001   On-site biological specimen collection     Firm-fixed-unit-price     Day

             and transportation  of specimens to

             the Contractor’s processing location 

X002   Reverse Transcriptase – Polymerase Chain Firm-fixed-unit-price   Each 

            Reaction testing for the SARS-CoV-2 virus,

            including collection of necessary biological

            specimens at the Contractor’s processing location   

1. Firm-fixed-price (see FAR 16.202) = Payment at negotiated firm-fixed-price.  Negotiated firm-fixed-price includes direct labor costs, direct non-labor costs, applicable indirect costs, and profit.

1. Firm-fixed-unit-price (FFUP) = Payment at negotiated firm-fixed-unit-price. Negotiated FFUP includes all direct costs, applicable indirect costs, and profit.

Anticipated Pricing Structure

CLIN + Description           Base Year    Option Year (OY)1   OY 2   OY3   OY 4   

X001. On-site (2401 E St.

NW Washington DC) biological

specimen collection and

transportation of specimens

to the Contractor’s processing

location for 180 personnel being

tested (includes all labor costs,

other direct costs, applicable

indirect costs, profit/fee)

X002. Reverse Transcriptase –

Polymerase Chain Reaction

testing for the SARS-CoV-2 virus,

including collection of necessary

biological specimens at the

Contractor’s processing location

(includes all labor costs, other

direct costs, applicable indirect

costs, profit/fee)

Attachments

• Draft Performance Work Statement
• Draft Pricing Tables
• Draft Relevant Experience Questionnaire